Core Viewpoint - Rosen Law Firm is reminding investors who purchased Capricor Therapeutics, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on September 15, 2025 [1] Group 1: Class Action Details - Investors who purchased Capricor securities between October 9, 2024, and July 10, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by September 15, 2025 [3] - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting their own achievements in this area [4] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4] - Rosen Law Firm has been recognized for its performance in securities class action settlements, being ranked No. 1 by ISS Securities Class Action Services in 2017 [4] Group 3: Case Specifics - The lawsuit alleges that Capricor provided misleading information regarding its lead cell therapy candidate, deramiocel, which is intended for treating cardiomyopathy associated with Duchenne muscular dystrophy [5] - Defendants allegedly made positive statements about obtaining a Biologics License Application from the FDA while concealing adverse facts about the drug's safety and efficacy data from its Phase 2 trial [5] - The misleading information is claimed to have led to shareholders purchasing securities at inflated prices, resulting in damages when the truth was revealed [5]

Group 1 - A class action lawsuit has been filed on behalf of purchasers of securities of Lantheus Holdings, Inc. for the period between February 26, 2025, and August 5, 2025 [1] - Investors who purchased Lantheus securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - The lawsuit alleges that Lantheus provided misleading statements regarding its competitive position and failed to disclose critical information about pricing dynamics for its product Pylarify [5] Group 2 - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including over $438 million for investors in 2019 [4] - The firm has been recognized for its leadership in securities class action settlements, being ranked No. 1 by ISS Securities Class Action Services in 2017 [4] - Investors are encouraged to select qualified counsel with a proven history in handling similar cases [4]

Core Viewpoint - A class action lawsuit has been filed against Charter Communications, Inc. for misleading statements regarding its business operations and the impact of the FCC's Affordable Connectivity Program ending, which allegedly led to investor losses during the specified Class Period [1][5]. Group 1: Lawsuit Details - The class action lawsuit covers purchasers of Charter Communications securities and options between July 26, 2024, and July 24, 2025 [1]. - The lawsuit claims that Charter Communications made false or misleading statements about its ability to manage the impact of the FCC's Affordable Connectivity Program ending, which affected internet customer declines and revenue [5]. - The lawsuit alleges that Charter's management failed to disclose the true risks associated with its business plans and earnings growth, leading to materially misleading statements about the company's operations and outlook [5]. Group 2: Legal Process and Participation - Investors who purchased securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested parties can join the class action by submitting a form or contacting the law firm directly, with a deadline to serve as lead plaintiff by October 13, 2025 [3][6]. - It is noted that no class has been certified yet, and investors are not represented by counsel unless they retain one [7].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Lockheed Martin securities between January 23, 2024, and July 21, 2025, of the September 26, 2025, deadline to become lead plaintiffs in a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Lockheed Martin securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by September 26, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Allegations Against Lockheed Martin - The lawsuit alleges that Lockheed Martin made false and misleading statements and failed to disclose critical information regarding its internal controls and risk management practices [5]. - Specific claims include Lockheed Martin's lack of effective internal controls over risk-adjusted contracts, inaccurate program reviews, and overstated capabilities in delivering contract commitments [5]. - As a result of these alleged misrepresentations, the lawsuit claims that investors suffered damages when the true details became public [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased SelectQuote, Inc. securities between September 9, 2020, and May 1, 2025, of the October 10, 2025, deadline to become lead plaintiffs in a class action lawsuit [1] Group 1: Class Action Details - Investors who purchased SelectQuote securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [2][5] - The lead plaintiff must file a motion with the Court by October 10, 2025, to represent other class members in the litigation [2] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time and has been ranked highly for its performance in securities class action settlements [3] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [3] Group 3: Allegations Against SelectQuote - The lawsuit alleges that SelectQuote made false and misleading statements and failed to disclose critical information regarding its business practices [4] - Specific allegations include directing Medicare beneficiaries to insurers that compensated SelectQuote, not providing unbiased comparisons, receiving illegal kickbacks, and non-compliance with laws and regulations [4] - The lawsuit claims that these actions led to misleading positive statements about SelectQuote's business, resulting in investor damages when the truth was revealed [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of RxSight, Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The class period for the lawsuit is from November 7, 2024, to July 8, 2025, and investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by September 22, 2025 [2]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and being ranked No. 1 for the number of settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [3]. Group 3: Case Allegations - The lawsuit alleges that RxSight made false and misleading statements regarding its sales and utilization, overstated demand for its products, and was unlikely to meet its financial guidance for fiscal year 2025 [4]. - The misleading statements led to investor damages when the true details about the company's performance were revealed [4].

Core Points - Rosen Law Firm is reminding investors who purchased Replimune Group, Inc. securities between November 22, 2024, and July 21, 2025, of the September 22, 2025, lead plaintiff deadline in a securities class action lawsuit [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting the firm [3] Case Details - The lawsuit alleges that Replimune's defendants made materially false and misleading statements regarding the IGNYTE trial, which the FDA deemed inadequate [5] - The claims suggest that the defendants overstated the trial's prospects, leading to investor damages when the true information was revealed [5] Legal Representation - Investors are encouraged to select qualified legal counsel with a successful track record in securities class actions [4] - The Rosen Law Firm has a history of significant recoveries for investors, including over $438 million in 2019 alone [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Fiserv, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The Class Period for the Fiserv common stock purchases is from July 24, 2024, to July 22, 2025 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by September 22, 2025 [2]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [3]. - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013 [3]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for clients [3]. Group 3: Case Allegations - The lawsuit alleges that Fiserv made false and misleading statements regarding its Clover platform, which was forced upon Payeezy merchants due to issues with the older Payeezy platform [4]. - It is claimed that Clover's revenue growth was artificially inflated by these forced conversions, masking a slowdown in new merchant business [4]. - The lawsuit further states that many former Payeezy merchants switched to competitors due to Clover's high pricing and compatibility issues, leading to a significant slowdown in Clover's growth [4].

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Dow Inc. securities for the period between January 30, 2025, and July 23, 2025, alleging that the company made false and misleading statements regarding its financial condition and ability to manage macroeconomic challenges [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that Dow Inc. overstated its ability to handle macroeconomic and tariff-related challenges, which negatively impacted its business and financial condition [5]. - The lawsuit alleges that Dow's public statements were materially false and misleading, particularly regarding competitive pressures, global sales demand, and product oversupply [5]. - Investors who purchased Dow Inc. securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Next Steps for Investors - Investors wishing to join the class action can do so by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must be appointed by October 28, 2025, to represent the interests of other class members in the litigation [1][3]. - Until a class is certified, investors are not represented by counsel unless they choose to retain one [7].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased CTO Realty Growth, Inc. securities between February 18, 2021, and June 24, 2025, of the upcoming lead plaintiff deadline on October 7, 2025 [1]. Group 1: Class Action Details - Investors who purchased CTO Realty securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by October 7, 2025 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been consistently ranked among the top firms for securities class action settlements [4]. Group 3: Case Allegations - The lawsuit alleges that CTO Realty Growth made false and misleading statements regarding the sustainability of its dividends and the profitability of its Ashford Lane property [5]. - It is claimed that the company's business and financial prospects were overstated, leading to investor damages when the true information became public [5].